Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Shenzhen Fushan Biotech Co. Ltd. currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This action is being handled by 1 distinct examiner, CAIN, JENNIFER LYNN, in 1 distinct art unit. As the busiest examiner for the company, CAIN, JENNIFER LYNN is responsible for 1 pending action. This concentrated prosecution profile indicates a singular focus for the company's current patent efforts.
With only 1 pending office action, the administrative oversight required for this portfolio is minimal. The use of 1 distinct art unit suggests that the pending matter is confined to a specific technical field. CAIN, JENNIFER LYNN is the only examiner involved, meaning the company's entire active workload is subject to a single individual's review. This centralization allows for a very focused legal strategy regarding the 1 pending office action. The Biotechnology & Pharmaceuticals area provides the technical context for this singular filing. Practitioners can expect a streamlined process given that 1 distinct examiner manages the entirety of the pending workload.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CAIN, JENNIFER LYNN | 1 | 43.5% | +67.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18609554 | STABLE RELEASE NUTRITIONAL TARGETING COMPOSITION AND ITS USE | CAIN, JENNIFER LYNN | — |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18609554 | STABLE RELEASE NUTRITIONAL TARGETING COMPOSITION AND ITS USE | CAIN, JENNIFER LYNN | 1655 | §103 | Final Rejection | — | Pending | Mar 19, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialShenzhen Fushan Biotech Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jennifer Lynn Cain has the most, with 1 of Shenzhen Fushan Biotech Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
